Quality of Recovery After Reversal With Neostigmine or Sugammadex.

• Status: Completed
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stony Brook University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• Participant must be willing and able to provide written informed consent for the study

• Participant must be greater than or equal to 18 years of age

• Participant must be ASA (American Society of Anesthesiologists) class I, II or III

• Planned use of neuromuscular blocking drugs

• Planned use of endotracheal intubation

• Planned for extubation to occur in the OR

Exclusion Criteria:

• ASA (American Society of Anesthesiologists) Class IV

• Age < 18 years old

• Inability to give oral or written consent

• Known or suspected neuromuscular disorder impairing neuromuscular function

• True allergy to muscle relaxants

• A (family) history of malignant hyperthermia

• A contraindication for neostigmine or sugammadex administration

• Serum creatinine level of greater than 2.0 mg/dL

• Surgery where the patient's arm is not available for neuromuscular monitoring

• A plan to extubate under deep anesthesia

• Pregnant